Examining heterogeneity in phase II trial designs may improve success in phase III

MeSH terms

• Antineoplastic Agents / therapeutic use*
• Benzenesulfonates / administration & dosage
• Clinical Trials, Phase II as Topic / standards*
• Clinical Trials, Phase III as Topic / standards*
• Confounding Factors, Epidemiologic
• Humans
• Neoplasms / drug therapy*
• Niacinamide / analogs & derivatives
• Phenylurea Compounds
• Pyridines / administration & dosage
• Randomized Controlled Trials as Topic / standards
• Research Design*
• Sorafenib
• Treatment Outcome